



Fax completed prior authorization request form to 800-854-7614 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned**

Pharmacy Coverage Guidelines are available at www.mercycareaz.org/providers/complecare-forproviders/pharmacy

Somatostatin Analogs Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagnosis

Member Information					
Member Name (first & last):		Date of Birth:		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Member ID:		City:		State:	
				Height:	
				Weight:	
Prescribing Provider Information					
Provider Name (first & last):		Specialty:		NPI#	
Office Address:		City:		State:	
				DEA#	
Office Contact:		Office Phone		Office Fax:	
				Zip Code:	
Dispensing Pharmacy Information					
Pharmacy Name:		Pharmacy Phone:		Pharmacy Fax:	
Requested Medication Information					
Preferred Agents:		<input type="checkbox"/> Octreotide		<input type="checkbox"/> Sandostatin Long Acting Release (LAR)	
Non-Preferred Agents:		<input type="checkbox"/> Signifor		<input type="checkbox"/> Somatuline Depot	
Are there any contraindications to formulary medications? If yes, please specify:		<input type="checkbox"/> Yes <input type="checkbox"/> No		<input type="checkbox"/> New request <input type="checkbox"/> Continuation of therapy request	
Medication request is NOT for an FDA approved, or compendia-supported diagnosis (circle one): Yes No		Diagnosis:		ICD-10 Code:	
Directions for Use:		Strength:		Dosage Form:	
		Quantity:		Day Supply:	
				Duration of Therapy/Use:	
What medication(s) has member tried and failed for this diagnosis?					
Turn-Around Time for Review					
<input type="checkbox"/> Standard – (24 hours)		<input type="checkbox"/> Urgent – waiting 24 hours for a standard decision could seriously harm life, health, or ability to regain maximum function, you can ask for an expedited decision. Signature: _____			
Clinical Information					
<input type="checkbox"/> Sandostatin LAR			<input type="checkbox"/> Somatuline Depot		
Baseline Testing:		<input type="checkbox"/> A1C or fasting glucose		<input type="checkbox"/> Thyroid-stimulating hormone	
				<input type="checkbox"/> Electrocardiography	
<input type="checkbox"/> Signifor			<input type="checkbox"/> Signifor (LAR)		
Baseline Testing:		<input type="checkbox"/> Potassium		<input type="checkbox"/> Thyroid-Stimulating Hormone	
		<input type="checkbox"/> Magnesium		<input type="checkbox"/> A1C or fasting plasma glucose	
		<input type="checkbox"/> Liver Function Tests		<input type="checkbox"/> Gallbladder Ultrasound	
				<input type="checkbox"/> Electrocardiography	
Additional Criteria Based on Indication					
<input type="checkbox"/> Acromegaly					
Member has ONE of the follow ing:		<input type="checkbox"/> Persistent disease follow ing radiotherapy and/or pituitary surgery		<input type="checkbox"/> Surgical resection is NOT an option as evidenced by ONE of the follow ing:	
				<input type="checkbox"/> Majority of tumor cannot be resected	
				<input type="checkbox"/> Member is a poor surgical candidate based on comorbidities	
				<input type="checkbox"/> Member prefers medical treatment over surgery OR refuses surgery	
Baseline IGF-1 meets ONE of the follow ing:		<input type="checkbox"/> ≥2 times the upper limit of normal for age		<input type="checkbox"/> Remains elevated despite a 6-month trial of maximally tolerated dose of cabergoline (unless member cannot tolerate, or has contraindication to cabergoline)	
<input type="checkbox"/> Carcinoid Tumor or Vasoactive Intestinal Polypeptide Secreting Tumor (VIPomas)					

<input type="checkbox"/> Cushing's Syndrome				
Has member had persistent disease after pituitary surgery OR surgery is NOT an option?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Did member have inadequate response, intolerable side effects OR contraindication to cabergoline?	<input type="checkbox"/> Yes <input type="checkbox"/> No
<input type="checkbox"/> Hepato-Renal Syndrome				
Will Octreotide be used in combination with midodrine and albumin?			<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Gastro-entero-pancreatic neuroendocrine tumor				
Has member had persistent disease after surgical resection OR is NOT a candidate for surgery?			<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Renewal Requests ONLY				
Response to therapy includes:	<input type="checkbox"/> A1C or fasting glucose	<input type="checkbox"/> TSH	<input type="checkbox"/> Electrocardiography	<input type="checkbox"/> Monitor for cholelithiasis AND discontinue if complications of cholelithiasis are suspected
<input type="checkbox"/> Acromegaly				
Decreased or normalized IGF-1 levels			<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Cushing's Syndrome				
Decreased or normalized cortisol levels			<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Signifor				
Liver Function Tests			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Additional information the prescribing provider feels is important to this review. Please specify below or submit medical records				

Signature affirms that information given on this form is true and accurate and reflects office notes.	
Prescribing Provider's Signature: _____	Date: _____

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required
Standard turnaround time is 24 hours. You can call 800-624-3879 to check the status of a request.